Spots Global Cancer Trial Database for atm gene mutation

Every month we try and update this database with for atm gene mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Combination Therapy in Cancers With Mutations in DNA Repair Genes	NCT05694715	Metastatic Soli... BRCA1 Mutation BRCA2 Mutation ATM Gene Mutati... PALB2 Gene Muta...	Niraparib Irinotecan	18 Years -	University of California, San Francisco
Prostate Cancer Genetic Risk Evaluation and Screening Study	NCT05129605	Prostatic Neopl... Prostate Cancer BRCA2 Mutation BRCA1 Mutation ATM Gene Mutati... MMR Mutation Lynch Syndrome Genetic Predisp...	Prostate cancer...	35 Years - 74 Years	Massachusetts General Hospital
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes	NCT02286687	Advanced Malign... ATM Gene Mutati... BRCA1 Gene Muta... BRCA2 Gene Muta... Metastatic Mali... PALB2 Gene Muta... Recurrent Malig... Refractory Mali...	Laboratory Biom... Pharmacological... Talazoparib	18 Years -	M.D. Anderson Cancer Center
Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion	NCT06033092	BRCA Mutation PALB2 Gene Muta... Ductal Carcinom... Lobular Carcino... ATM Gene Mutati... CHEK2 Gene Muta... CDH1 Gene Mutat... RAD51C Gene Mut... RAD51D Gene Mut...	Tamoxifen 10 mg... Intermittent ca... Step counter De...	18 Years - 70 Years	European Institute of Oncology
Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion	NCT06033092	BRCA Mutation PALB2 Gene Muta... Ductal Carcinom... Lobular Carcino... ATM Gene Mutati... CHEK2 Gene Muta... CDH1 Gene Mutat... RAD51C Gene Mut... RAD51D Gene Mut...	Tamoxifen 10 mg... Intermittent ca... Step counter De...	18 Years - 70 Years	European Institute of Oncology
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency	NCT03442556	ATM Gene Mutati... BRCA1 Gene Muta... BRCA2 Gene Muta... Castration Leve... Castration-Resi... Homologous Reco... Prostate Carcin... PSA Level Great... PSA Progression Stage IV Prosta...	Carboplatin Docetaxel Laboratory Biom... Rucaparib Camsy... Rucaparib	18 Years -	University of Washington
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors	NCT06177171	BRCA1 Mutation BRCA2 Mutation BRCA Mutation PALB2 Gene Muta... Checkpoint Kina... ATM Gene Mutati...	Olaparib ASTX727	18 Years -	University of California, San Francisco
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	NCT04030559	ATM Gene Mutati... BRCA1 Gene Muta... BRCA2 Gene Muta... BRIP1 Gene Muta... CDK12 Gene Muta... CHEK1 Gene Muta... CHEK2 Gene Muta... DNA Damage Resp... DNA Repair Gene... FANCA Gene Muta... FANCD2 Gene Mut... FANCL Gene Muta... GEN1 Gene Mutat... NBN Gene Mutati... Prostate Carcin... RAD51 Gene Muta... RAD51C Gene Mut...	Niraparib Niraparib Tosyl... Radical Prostat...	18 Years -	University of California, Davis
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer	NCT03377556	ATM Gene Mutati... ATR Gene Mutati... BARD1 Gene Muta... BRCA1 Gene Muta... BRCA2 Gene Muta... BRIP1 Gene Muta... CHEK1 Gene Muta... CHEK2 Gene Muta... FANCA Gene Muta... FANCC Gene Muta... FANCD2 Gene Mut... FANCF Gene Muta... FANCM Gene Muta... NBN Gene Mutati... PALB2 Gene Muta... RAD51 Gene Muta... RAD51B Gene Mut... RAD54L Gene Mut... Recurrent Squam... RPA1 Gene Mutat... Stage IV Squamo...	Laboratory Biom... Pharmacological... Talazoparib	-	SWOG Cancer Research Network
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes	NCT02286687	Advanced Malign... ATM Gene Mutati... BRCA1 Gene Muta... BRCA2 Gene Muta... Metastatic Mali... PALB2 Gene Muta... Recurrent Malig... Refractory Mali...	Laboratory Biom... Pharmacological... Talazoparib	18 Years -	M.D. Anderson Cancer Center
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	NCT04030559	ATM Gene Mutati... BRCA1 Gene Muta... BRCA2 Gene Muta... BRIP1 Gene Muta... CDK12 Gene Muta... CHEK1 Gene Muta... CHEK2 Gene Muta... DNA Damage Resp... DNA Repair Gene... FANCA Gene Muta... FANCD2 Gene Mut... FANCL Gene Muta... GEN1 Gene Mutat... NBN Gene Mutati... Prostate Carcin... RAD51 Gene Muta... RAD51C Gene Mut...	Niraparib Niraparib Tosyl... Radical Prostat...	18 Years -	University of California, Davis
Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer	NCT03432676	ATM Gene Mutati... Deleterious BRC... Deleterious BRC... Homologous Reco... Pancreatic Duct... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre...	Epacadostat Pembrolizumab	18 Years -	M.D. Anderson Cancer Center
A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors	NCT06337630	Solid Tumor	PLX038 + Tuvuse...	18 Years -	Institut Curie
Olaparib In Metastatic Breast Cancer	NCT03344965	Metastatic Brea... Invasive Breast... Somatic Mutatio... Somatic Mutatio... CHEK2 Gene Muta... ATM Gene Mutati... PALB2 Gene Muta... RAD51 Gene Muta... BRIP1 Gene Muta... NBN Gene Mutati...	Olaparib	18 Years -	Beth Israel Deaconess Medical Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: